Is PATH a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

998 people get PATH articles and Market Currents by email alert.

Get email alerts on PATH »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

NuPathe Gets FDA Approval: What's Next For The Stock
David Zanoni • Mon, Jan 21 • 31 Comments
NuPathe And Its Upcoming PDUFA Decision
Justin Kuepper • Wed, Jan 2 • 23 Comments
Buy NuPathe: When An FDA Rejection Creates An Opportunity
Helix Investment Research • Thu, Nov 29, 2012 • 15 Comments
Nupathe Pharma: Potentially A Triple In Stock Price On FDA Approval
Scott Matusow • Wed, Oct 17, 2012 • 46 Comments
NuPathe Facts On A Very Undervalued Play
Bob's Stocks • Thu, Oct 4, 2012 • 11 Comments
NuPathe Pharma: A Possible Double On The Horizon
Scott Matusow • Wed, Mar 14, 2012 • 25 Comments
Nupathe's Zelrix Going Down A Path With Multiple Headwinds
ScriptVolume • Fri, Dec 9, 2011
NuPathe: Beaten Down Stock Offers Opportunity Into Zelrix Trial Results
Alex Shadunsky • Tue, Aug 9, 2011 • 7 Comments
NuPathe Awaits FDA Decision for Migraine Skin Patch
Mike Havrilla • Wed, Apr 27, 2011 • 3 Comments
NuPathe Trades at Discount to IPO Price with Near-Term FDA Filing
Mike Havrilla • Tue, Sep 21, 2010
Biotech IPO: NuPathe
SA Editor Mohit Manghnani • Fri, Aug 6, 2010

Buy NuPathe: When An FDA Rejection Creates An Opportunity
Helix Investment Research • Thu, Nov 29, 2012 • 15 Comments

Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
3 Biotechs With Upcoming Product Launches
Markus Aarnio • Thu, Apr 11 • 9 Comments
Investment Implications Of The Acquisition Of MAP Pharmaceuticals By Allergan
Smith On Stocks • Thu, Jan 24 • 5 Comments
FDA Decision On MAP's Levadex Approaching, Stock Starting To Reflect Optimism
PropThink • Thu, Jan 10 • 13 Comments
2 Impending Biotech Catalysts To Start Off 2013
Brian L. Wilson • Thu, Jan 3 • 9 Comments
5 Biotechs With January FDA Decision Date Catalysts
David Zanoni • Mon, Dec 17, 2012
Selling FDA Approvals: Latest Results
BinaryLeverage • Thu, Dec 13, 2012 • 14 Comments
5 Pharmaceutical Companies With PDUFA Dates In Q1 2013
Markus Aarnio • Thu, Aug 9, 2012 • 11 Comments
As Hoped, Biotech And Drugs March To Their Own Beat
Joe Springer • Tue, Aug 7, 2012 • 1 Comment
Bonus Round: 9 Stocks Follow-Up
James Stocklasar Thomas Jr. • Mon, Apr 23, 2012 • 17 Comments
MAP Pharma: Still Potentially A Good Short Sell
Scott Matusow • Tue, Apr 17, 2012 • 8 Comments
16 Biotech Stocks Sold Off By Hedge Funds
Kapitall • Mon, Apr 2, 2012 • 1 Comment
Tuesday's Bio-Pharma Watch List
Scott Matusow • Tue, Mar 27, 2012 • 11 Comments
A Review Of My Last 3 Small Cap Bio-Pharma Picks
Scott Matusow • Mon, Mar 19, 2012 • 23 Comments
7 Biotech Stocks Being Snapped Up By Insiders
Kapitall • Fri, Mar 16, 2012 • 2 Comments
Why Antares Pharma Should Be On Your List For Long-Term Investment
Scott Matusow • Fri, Mar 16, 2012 • 24 Comments
12 Winning Streak Stocks With Significant Insider Buying
Kapitall • Sun, Mar 4, 2012 • 2 Comments
Biotech Class Of 2010: IPOs Revisited
Steven Breazzano • Wed, Jan 4, 2012 • 3 Comments
Life Science Venture Capital For Retail Investors
Bryce Istvan • Mon, Nov 28, 2011 • 3 Comments
John Burbank And Insiders Are Bullish On These 18 Stocks
Insider Monkey • Mon, Oct 24, 2011

NuPathe Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14
NuPathe Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 26
NuPathe's CEO Discusses Q2 2013 Results - Earnings Call Transcript
Mon, Nov 12, 2012
NuPathe Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 14, 2012 • 2 Comments

NuPathe Announces Allowance of Additional U.S. Patent Application for ZECUITY

Marketwire (May 28, 2013)
NuPathe Announces First Quarter 2013 Financial Results and Operational Highlights

Marketwire (May 14, 2013)
NuPathe Announces Allowance of Additional U.S. Patent Application for NP201

Marketwire (May 13, 2013)
NuPathe to Host Conference Call to Discuss First Quarter 2013 Results on Tuesday, May 14, 2013

Marketwire (May 7, 2013)
NuPathe Announces Allowance of U.S. Patent Application for NP201

Marketwire (Apr 25, 2013)
NuPathe Announces Fourth Quarter and Full Year 2012 Financial Results and Operational Highlights

Marketwire (Mar 26, 2013)
NuPathe to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Results on Tuesday, March 26, 2013

Marketwire (Mar 19, 2013)
NuPathe to Present at the Leerink Swann 2013 Global Healthcare Conference

Marketwire (Feb 6, 2013)
NuPathe's Zecuity Approved by the FDA for the Acute Treatment of Migraine

Marketwire (Jan 17, 2013)
NuPathe Announces Allowance of Additional U.S. Patent Application for Zecuity

Marketwire (Jan 2, 2013)
NuPathe Secures $8.5 Million Term Loan

Marketwire (Nov 27, 2012)
NuPathe Announces Third Quarter 2012 Financial Results and Operational Highlights

Marketwire (Nov 12, 2012)
NuPathe to Present at the 9th Annual Lazard Healthcare Conference

Marketwire (Nov 7, 2012)
NuPathe to Host Conference Call to Discuss Third Quarter 2012 Results on Monday, November 12, 2012

Marketwire (Nov 5, 2012)
NuPathe Announces Closing of $28 Million Private Placement and Changes to Its Board of Directors

Marketwire (Oct 23, 2012)
NuPathe Granted Financial Viability Exception by NASDAQ

Marketwire (Oct 12, 2012)
NuPathe to Present at the Safeguard Scientifics Investor Day 2012

Marketwire (Oct 8, 2012)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 26, 2012)
NuPathe Announces $28 Million Private Placement

Marketwire (Sep 25, 2012)
NuPathe Announces Second Quarter 2012 Financial Results and Operational Highlights

Marketwire (Aug 14, 2012)

PATH vs. ETF Alternatives

Company Description

We are a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. Following are the key information about our existing product candidates. We hold... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, June 6, 1:18 PM Shares of NuPathe (PATH -1%) are lower again today, extending a week-long decline on no specific news. The stock took an accelerated turn to the downside in early trading, cratering nearly 14% on what looks like capitulation selling before recovering most of the losses. Comment! [Healthcare, On the Move]
Friday, May 17, 5:42 PM After-hours top gainers, as of 5:15 p.m.: GAIA +7.6%. ADK +6.4%. PATH +5.3%. GST +4.2%. DQ +3.3%.
After-hours top losers: DATA -5.1%. QEP -3.8%. CPRT -3.8%. RPAI -3.6%. EA -2.3%. Comment! [On the Move]
Tuesday, May 14, 2:15 PM NuPathe (PATH -2.4%) slides after posting a Q1 loss of $0.21 per share earlier today, versus the consensus loss of $0.19 per share. The company did not record revenues for the quarter, as expected. The miss can be attributed to dilution stemming from the automatic conversion of its Series A Preferred Stock, which was triggered in February, resulting in the conversion of 100% of the outstanding into common stock, as well as the termination of a "full ratchet" anti-dilution feature on warrants issued in connection with the preferred stock in October 2012. 3 Comments [Healthcare, Earnings, On the Move]
Tuesday, March 26, 11:47 AM NuPathe (PATH -6.6%) slips after its Q4 EPS loss came in much greater than expected. Net loss, including items, was $19.1M, wider than the loss reported in the prior year period. Despite the miss, CEO Armando Anido was upbeat in his comments, saying the company remains focused on securing commercial partners and preparing for the commercial launch of Zecuity, the first and only prescription migraine patch, which is expected in Q4. Comment! [Healthcare, On the Move, Earnings]
Tuesday, March 26, 9:15 AM Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move]
Tuesday, March 26, 7:37 AM NuPathe Inc (PATH): Q4 EPS of -$1.15. Shares +3.8% premarket. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Friday, January 18, 9:10 AM Premarket gainers: PATH +16%. LIFE +12%. NEWL +8%. RIMM +8%. MS +7%. SNE +7%. GERN +5%.
Losers: FNSR -10%. TSRX -9%. WIT -8%. COF -7%. INTC -6%.
2 Comments [On the Move]
Thursday, January 17, 7:56 PM The FDA approves NuPathe's (PATH) Zecuity for the acute treatment of migraine with or without aura in adults. The drug is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin. Shares surge +18% after resuming trade following an earlier halt. 3 Comments [Healthcare, On the Move]
Thursday, January 17, 6:02 PM Shares of NuPathe (PATH) have been halted with news pending. The company has a PDUFA date today for its Zecuity migraine patch. Shares -1% AH. Comment! [Healthcare]
Thursday, January 17, 5:40 PM After-hours top gainers, as of 5:15 p.m.: AM +9%. ARAY +4%. SOXS +3%. EGLE +3%. ONXX +2%.
After-hours top losers: COF -8%. TSRX -6%. PATH -5%. INTC -4%. MAKO -3%. Comment! [On the Move]
Thursday, January 17, 9:10 AM Premarket gainers: NEWL +64%. KSWS +48%. PATH +11%. CBS +9%. ROYL +8%. NUS +6%.
Losers: CLSN -10%. AVEO -5%. Comment! [On the Move]
Wednesday, January 2, 2:00 PM NuPathe (PATH +2.5%) says the U.S. Patent & Trademark Office has accepted its patent application for iontophoretic patches, a migraine treatment containing the company's proprietary hydrogel polyamine formulation. The company expects the patent to be issued within the next few months, and should provide additional patent protection for its existing migraine treatment Zecuity. Comment! [Healthcare, On the Move]
Friday, December 21, 2012, 5:38 PM After-hours top gainers, as of 5:15 p.m.: TFSL +6%. PACT +3%. PBRA +3%. DANG +3%. OIBRC +2%.
After-hours top losers: ALXA -13.13%. PATH -7%. SVU -4%. TXT -4%. NSU -4%. 1 Comment [On the Move]
Monday, November 12, 2012, 3:38 PM Shares of NuPathe (PATH -2%) are lower today after reporting a Q3 loss of $0.42 per share, below the Street consensus of a $0.36 per share loss. The company didn't report revenues for the quarter, which was expected. On a per share basis, earnings sank 29% Y/Y as the company's bottom line was negatively impacted by higher costs associated with separation expenses related to the resignation of its former CEO as well as the elimination of 15 full-time positions. Comment! [Healthcare, Earnings, On the Move]
Tuesday, October 9, 2012, 9:05 AM NuPathe (PATH) intends to reduce its workforce by half in order to cut expenses and focus on receiving approval for its NP101 migraine patch. The company, which has almost 40 employees, will also lower marketing costs, and postpone the application for its NP202 drug for schizophrenia and bipolar disorder until it finds a partner. NuPathe is trying to raise $28M in financing. (PR) Comment! [Healthcare]
Wednesday, September 26, 2012, 12:45 PM Midday top 10 gainers: LPHI +112%. CTC +18%. AM +17%. STSI +15%. KCG +11%. WCBO +11%. CAMP +10%. DIAL +10%. SCMP +10%. SVN +8%.
Top 10 Losers: PATH -27%. BTH -19%. OMN -14%. RMKR -13%. CPRX -13%. TISA -12%. GEVO -12%. MITK -12%. OINK -12%. TSTC -11%. Comment! [On the Move]

Ryan Mallory
Fuinhaz Setups for March 27 2013 | $AIXG $BSFT $CETV $EA $PATH $RFMD $SONC $SWHC $THRX | SharePlanner http://bit.ly/10Phsbd
Mar 27, 9:23 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Perkins Cove
$PATH, buy @3.46 pre mkt. Daytrade.
Jan 22, 8:05 AM
Reply (8)

• !Report Abuse
View all 8 replies
Perkins Cove: Yup! Shoulda, woulda, coulda......grin
Jan 23, 5:41 AM
• !Report Abuse
Ocean Man: Don't feel bad, I sold a GOOG call yesterday. :(
Jan 23, 8:36 AM
• !Report Abuse
Add a reply...

140 characters

pagreen1966
$PATH flat yesterday because still no announcement of partner. Expect news within the month.
Jan 19, 6:35 AM
Reply (1)

• !Report Abuse
View all 1 replies
cudan: How do you figure that time frame?
Feb 22, 6:18 AM
• !Report Abuse
Add a reply...

140 characters

Derek2012
Disappointed in the way $PATH is moving today
Jan 18, 10:52 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nsahbti
Isn't $PATH supposed to be approved today?
Jan 17, 3:26 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nahodny Okoloiduci
bear raid seen on $PATH today http://bit.ly/SiaqdR
Jan 8, 11:56 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
Technical Notes on $PATH http://bit.ly/WF27de
12/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
I bought $PATH Major catalyst upcoming, good chance at a triple on FDA approval
10/16/12
Reply (30)

• !Report Abuse
View all 30 replies
Scott Matusow: and that is all you or anyone else should be concerned with
10/29/12
• !Report Abuse
Scott Matusow: so no, I don't believe u do well in the market at all, no one who chides success can possibly be a real market winner with any real money
10/29/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://stks.co/f2AV New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, $AMRN, $HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN, $SLXP
7/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/ObIXDN New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, /4HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN
7/19/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: AMRN
7/19/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

pagreen1966
$PATH flat yesterday because still no announcement of partner. Expect news within the month.
Jan 19, 6:35 AM
Reply (1)

• !Report Abuse
View all 1 replies
cudan: How do you figure that time frame?
Feb 22, 6:18 AM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$PATH, buy @3.46 pre mkt. Daytrade.
Jan 22, 8:05 AM
Reply (8)

• !Report Abuse
View all 8 replies
Perkins Cove: Yup! Shoulda, woulda, coulda......grin
Jan 23, 5:41 AM
• !Report Abuse
Ocean Man: Don't feel bad, I sold a GOOG call yesterday. :(
Jan 23, 8:36 AM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I bought $PATH Major catalyst upcoming, good chance at a triple on FDA approval
10/16/12
Reply (30)

• !Report Abuse
View all 30 replies
Scott Matusow: and that is all you or anyone else should be concerned with
10/29/12
• !Report Abuse
Scott Matusow: so no, I don't believe u do well in the market at all, no one who chides success can possibly be a real market winner with any real money
10/29/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/ObIXDN New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, /4HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN
7/19/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: AMRN
7/19/12
• !Report Abuse
Add a reply...

140 characters

SDRibble
anyone know what's happening with PATH?
6/26/12
Reply (1)

• !Report Abuse
View all 1 replies
mojojojo1: momentum trade ?
6/26/12
• !Report Abuse
Add a reply...

140 characters

mojojojo1
look at the volume for PATH ,it seems few players with deep pockets.
4/30/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: I like the potential for PATH as a long, analysts are very bullish, $10 pps target. But I got everything tied up in AMRN and IBIO, as longs
5/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$IBIO and $PATH because both offer the biggest multi bag potential if things work out for them $PSDV as well
4/12/12
Reply (1)

• !Report Abuse
View all 1 replies
Winning Will: Scott, good news out for HZNP .you still holding shares? I bought in at 3.70 sold a small portion at 4.25 before it fell. Thnks 4 this one!
4/12/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
PATH went down to my short term target of $4. like this one a lot for a double this year. grossly undervalued. was recently as high as $5.10
3/20/12
Reply (18)

• !Report Abuse
View all 18 replies
Scott Matusow: that was the initial public offering, they need another one, as the can use the money and the stock needs a bit more liquidity
3/23/12
• !Report Abuse
Rodney_Braswell: I will take that. I am not going to do anything with it. I am just going to let it sit there until...
3/23/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
PATH at 3.84? Thinking about jumping in
3/21/12
Reply (5)

• !Report Abuse
View all 5 replies
NightRaider: That was not expected. Where no confidence I keep zero trail stops
3/23/12
• !Report Abuse
Winning Will: how do you think we will fair up until we get some updates on the pipeline
3/23/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I recommend Nupathe Pharma (PATH) as a strong buy.
3/14/12
Reply (10)

• !Report Abuse
View all 10 replies
ArincTheAdanian: You are Awesome. Thanks indeed... Agree w/ all of the medical rationale mentioned within your blog!
3/15/12
• !Report Abuse
ArincTheAdanian: You are Awesome. Thanks indeed... Agree w/ all of the medical rationale mentioned within your blog!
3/15/12
• !Report Abuse
Add a reply...

140 characters

PATH NuPathe Inc.

PATH

NuPathe Inc.